THE Therapeutic Goods Administration is proposing allowing advertising of emergency contraception drug ulipristal, with an Appendix H listing of the item one of the interim decisions by the Advisory Committee on Medicines Scheduling released yesterday.
Other proposals include new scheduling for ibuprofen, penciclovir and loratidine.
The ACMS is suggesting loratidine be exempt from scheduling in preparations containing 10mg or less in packs of up to ten when used in kids from six years of age for the treatment of allergic rhinitis.
Penciclovir is also set to be exempt from scheduling in preparations containing 1% or less for the treatment of herpes labialis.
Ibuprofen's scheduling will allow S3 versions in a modified release dosage form, as well as a new entry for the NSAID in Appendix H because "there is a public health interest to inform consumers about pain relief options through advertising" - see tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 May 17